NCT07590193PHASE1RecruitingAccepts Healthy Volunteers
A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Amgen
Start Date
6/11/2026
Completion Date
10/2/2027
Summary
The main objective of this trial is to assess the safety and tolerability of AMG 127 as single dose and multiple doses in healthy participants and participants with type 2 diabetes mellitus (T2DM).
Eligibility Criteria
Age Range: 18 years to 75 years
Inclusion Criteria for Part A and B
* Participant must be 18-65 years of age
* Participant must be overtly healthy
Inclusion Criteria for Part C
* Participant must be 40-75 years of age
* Confirmed diagnoses of T2DM
Exclusion Criteria for Part A and B
* History of hypotension, syncope, or orthostatic intolerance
* Systolic blood pressure \>140 millimeters of mercury (mmHg) or diastolic blood pressure \>90 mmHg
Exclusion Criteria for Part C
* Hemoglobin A1c (HbA1c) \>10% within the last 3 months
* History of hypotension, syncope, or orthostatic intolerance
* Systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg
Interventions
DRUG
AMG 127
DRUG
Placebo
Conditions
Diabetes Mellitus, Type 2
Locations
Translational Clinical Research LLC
Aventura, Florida 33180
United States